Duke University

The UAB Research Foundation (the University of Alabama at Birmingham)

Los Alamos National Security, LLC

Beth Israel Deaconess Medical Center, Inc.

Los Alamos Security, LLC

Carla L Kuiken

William M Fischer

Karina Yusim

Barton F Haynes

Bette T Korber

Beatrice H Hahn

Norman L Letvin

James Theiler

Simon J Perkins

Tanmoy Bhattacharya

Bette T M Korber

The disclosure generally relates to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same.

Nucleic acids encoding mosaic HIV-1 gag proteins

The present invention relates to mosaic HIV-1 group M Gag sequences and to a composition comprising same.

Human immunodeficiency virus type 1 clade M mosaic gag polypeptides

The invention relates to immunogenic compositions useful as HCV vaccines. Provided are HCV mosaic polypeptide and nucleic acid compositions which provide higher levels of T-cell epitope coverage while minimizing the occurrence of unnatural and rare epitopes compared to natural HCV polypeptides and consensus HCV sequences.

Mosaic protein and nucleic acid vaccines against hepatitis C virus

The present invention relates to mosaic clade M HIV-1 Nef polypeptides and to compositions comprising same. The polypeptides of the invention are suitable for use in inducing an immune response to HIV-1 in a human.

Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins

Growing community of inventors

Santa Fe, NM, United States of America

Carla L Kuiken